Group One Trading
CADL icon

Group One Trading’s Candel Therapeutics CADL Stock Holding History

Group One Trading’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$124K Sell
25,300
-10,000
-28% -$54.4K ﹤0.01% 4535
2025
Q4 		$199K Sell
35,300
-146,900
-81% -$790K ﹤0.01% 4371
2025
Q3 		$929K Sell
182,200
-71,800
-28% -$415K ﹤0.01% 3113
2025
Q2 		$1.29M Buy
254,000
+58,800
+30% +$303K ﹤0.01% 2540
2025
Q1 		$1.1M Buy
195,200
+108,500
+125% +$887K ﹤0.01% 2378
2024
Q4 		$753K Buy
86,700
+81,200
+1,476% +$480K ﹤0.01% 2831
2024
Q3 		$38.1K Buy
5,500
+200
+4% +$1.24K ﹤0.01% 4825
2024
Q2 		$32.9K Buy
+5,300
New +$39.8K ﹤0.01% 4845

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading's CADL Position: Q1 2026 in Review

Group One Trading reduced its Candel Therapeutics (CADL) stake by 1.5% in Q1 2026, selling an estimated $735 and leaving 8,760 shares worth $42.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5378.

Group One Trading first reported a position in CADL in Q4 2025 and has held it in 2 quarters since. The position peaked at $50.3K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Group One Trading held 8,760 shares of Candel Therapeutics worth $42.9K as of Q1 2026.
  • Group One Trading sold 135 Candel Therapeutics shares in Q1 2026, an estimated $735.
  • Candel Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #5378 holding.
  • Group One Trading first reported a position in Candel Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Group One Trading's Candel Therapeutics position peaked at $50.3K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.